glp-1 law firm Agenda GLP-1 Vision Loss Lawsuits |

Lucie, necessitates clinical oversight, careful titration, laboratory monitoring, and personalized treatment plans we take no shortcuts

Potential implications of the new pharmacotherapies on obesity management The mean WL in clinical trials with the most efficacious new obesity pharmacotherapies ranges between 15% and 25% at 1 year (and it may be even higher for some agents that have not reached weight plateau at study completion)

PubMed Kateel R et al

Decreased urination or dark urine : Oliguria or concentrated urine may signal dehydration, particularly if accompanied by persistent nausea, vomiting, or diarrheacommon side effects of GLP-1 medications

Several SURMOUNT studies in patients with obesity are ongoing ( In the SURPASS-1 study, which enrolled 705 non-target T2DM patients with diet and physical activity intervention, the efficacy, safety, and tolerability of tirzepatide and a placebo were compared

The health implications of these changes run deep